Now showing items 1-3 of 3

    • Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model 

      Duquette, Mark; Sadow, Peter M.; Husain, Amjad; Sims, Jennifer N.; Antonello, Zeus A.; Fischer, Andrew H.; Song, Chen; Castellanos-Rizaldos, Elena; Makrigiorgos, G. Mike; Kurebayashi, Junichi; Nose, Vania; Van Hummelen, Paul; Bronson, Roderick T.; Vinco, Michelle; Giordano, Thomas J.; Dias-Santagata, Dora; Pandolfi, Pier Paolo; Nucera, Carmelo (Impact Journals LLC, 2015)
      BRAFV600E mutation exerts an essential oncogenic function in many tumors, including papillary thyroid carcinoma (PTC). Although BRAFV600E inhibitors are available, lack of response has been frequently observed. To study ...
    • Ossifying Parotid Carcinoma ex Pleomorphic Adenoma 

      Mohan, Suresh; Puram, Sidharth V.; Yarlagadda, Bharat; Nosé, Vania; Deschler, Daniel G. (Hindawi Publishing Corporation, 2015)
      We present a unique case of an extensively ossified carcinoma ex pleomorphic adenoma (CXPA) in a 76-year-old man with a five-year history of a slowly growing parotid mass. Fine-needle aspiration of the mass was nondiagnostic. ...
    • SCF\(^{β-TRCP}\) Suppresses Angiogenesis and Thyroid Cancer Cell Migration by Promoting Ubiquitination and Destruction of VEGF Receptor 2 

      Shaik, Shavali; Nucera, Carmelo; Inuzuka, Hiroyuki; Gao, Daming; Garnaas, Maija; Frechette, Gregory Martin; Harris, Lauren; Wan, Lixin; Fukushima, Hidefumi; Husain, Amjad; Nose, Vania; Fadda, Guido; Sadow, Peter Mark; Goessling, Wolfram; North, Trista Elizabeth; Lawler, Jack William; Wei, Wenyi (The Rockefeller University Press, 2012)
      The incidence of human papillary thyroid cancer (PTC) is increasing and an aggressive subtype of this disease is resistant to treatment with vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. VEGFR2 promotes ...